Patent Infringement and the Doctrine of Equivalents: Beyond Literal Claim Language

---

A patent protects more than just the exact words of its claims. Under the doctrine of equivalents, a competitor may still infringe a patent even if it does not copy the invention word-for-word—provided the competing product performs substantially the same function in substantially the same way to achieve substantially the same result. The Supreme Court clarified this rule in Smith Kline Beckman Corporation v. Court of Appeals and Tryco Pharma Corporation (G.R. No. 126627, August 14, 2003), a case that also reminds patent holders of the strict evidentiary burden they carry.

The Dispute: Albendazole vs. Methyl 5 Propylthio-2-Benzimidazole Carbamate

Smith Kline Beckman Corporation held Philippine Letters Patent No. 14561 for a compound called methyl 5 propylthio-2-benzimidazole carbamate, an anthelmintic used to treat parasite infections in animals. The patent claims covered the compound itself, along with methods and compositions using it.

Tryco Pharma Corporation manufactured and sold Impregon, a veterinary drug whose active ingredient was Albendazole. Smith Kline sued Tryco for patent infringement, arguing that Albendazole was substantially the same as its patented compound. The word "Albendazole" never appeared in Letters Patent No. 14561, but Smith Kline insisted that the doctrine of equivalents should apply.

The Legal Test: Function, Means, and Result

The Supreme Court acknowledged the doctrine of equivalents as a valid principle in Philippine patent law. Infringement occurs when a device "appropriates a prior invention by incorporating its innovative concept and, although with some modification and change, performs substantially the same function in substantially the same way to achieve substantially the same result."

But the Court stressed that this is a three-part test. A patent holder must prove all three elements: (1) substantially the same function, (2) substantially the same way or means of operation, and (3) substantially the same result. Merely showing that two compounds achieve the same outcome is not enough.

Why Smith Kline Lost

Smith Kline failed to satisfy this burden. Its evidence showed only that both Albendazole and the patented compound were anthelmintic agents—that is, both neutralized parasites in animals. This establishes identity of result, but nothing more.

The Court found no evidence explaining how Albendazole works to eliminate parasites, let alone proof that its method or means of operation was substantially the same as that of methyl 5 propylthio-2-benzimidazole carbamate. Smith Kline's witness, its general manager, was not qualified as an expert on chemical compounds, so his testimony carried little weight.

The Court also rejected Smith Kline's argument based on divisional applications. A divisional application arises when an original application claims multiple independent inventions; the applicant must "divide" the claims among separate patents. The fact that methyl 5 propylthio-2-benzimidazole carbamate was the subject of a divisional application actually suggested that it was a distinct invention from Albendazole, not that the two were interchangeable.

A Note on Damages

Although Tryco won on the infringement issue, the Supreme Court deleted the awards of actual damages and attorney's fees. The claimed lost profits—P330,000.00, computed as 30% of alleged monthly sales for eleven months—rested only on the testimonies of Tryco's officers. The Court required documentary evidence to substantiate a claim for actual or compensatory damages with reasonable certainty.

Instead, the Court awarded Tryco P20,000.00 as temperate or moderate damages under Article 2224 of the Civil Code, recognizing that Tryco suffered some pecuniary loss whose exact amount could not be established with certainty.

Practical Takeaways

• The doctrine of equivalents is real but demanding. A patent holder cannot rely on similarity of results alone. To prove infringement under this doctrine, one must show that the accused product performs substantially the same function, in substantially the same way, to achieve substantially the same result.
• Patent claims are boundaries. When the language of a patent's claims is clear, the patentee is bound by it and cannot claim anything beyond it. Courts will not enlarge a patent beyond what the inventor claimed and the patent office allowed.
• Evidence matters. Expert testimony is crucial in technical patent cases. A witness who is not qualified as an expert on the relevant technology may not be able to carry the patent holder's burden of proof.
• Damages require proof. Claims for actual damages, including lost profits, must be supported by competent documentary evidence. Testimonial estimates alone may not suffice; temperate damages may be awarded instead where the exact loss cannot be proven.

This article is general information and not legal advice. For your specific situation, consult a lawyer or ask ASG Legal AI.